Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07403097 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of CD19 CAR-T Therapy for Refractory SLE

Name: Study of CD19 CAR-T Therapy for Refractory SLE — clinical trial record (NCT07403097)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2026-02

View on ClinicalTrials.gov ↗

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Lupus (SLE)

648 trials monitored

See 25 trials at risk

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.

Trial Details

NCT Number	NCT07403097
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Systemic Lupus Erythematosus
Enrollment	18 participants
Start Date	2026-02
Primary Completion	2028-04 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-11